Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Selling, General & Admin	-70.88	-49.01	-24.58
Research & Development	-214.71	-167.87	-68.42
Total Operating Expenses	-285.6	-216.87	-93
Operating Income	-285.6	-216.87	-93
Interest Income	30.03	34.74	9.02
Total Non-Operating Income (Expense)	30.03	34.74	9.02
Pretax Income	-255.57	-182.13	-83.99
Provision for Income Taxes	-0.28	-0.02	-
Net Income	-255.84	-182.15	-83.99
Net Income to Common	-255.84	-182.15	-83.99
Shares Outstanding (Basic)	61	55	25
Shares Outstanding (Diluted)	61	55	25
Shares Change (YoY)	9.96%	120.72%	-
EPS (Basic)	-4.22	-3.30	-3.36
EPS (Diluted)	-4.22	-3.30	-3.36
Free Cash Flow	-232.6	-172.33	-74.93
Free Cash Flow Per Share	-3.83	-3.12	-3.00
EBITDA	-284.18	-216.68	-93
EBIT	-285.6	-216.87	-93
Effective Tax Rate	0.11%	0.01%	0.00%

Updated Mar 2, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q